Poland’s trusted pharmacy wholesaler with a high-upside clinical-trials option—NEUCA compounds defensively if it can turn Humaneva profitable and avoid a regulatory margin cut.
Overview
NEUCA S.A. is a Polish healthcare compounder combining a dominant, stable pharmaceutical distribution franchise with high-growth optionality in clinical trials, medical services, and own-brand production. The wholesale segment is the revenue backbone, with ~30% overall share and a leading ~39%+ share of independent pharmacies, supported by modern centralized logistics delivering thousands of SKUs nationwide to ~12,000 pharmacies and many hospitals. NEUCA’s differentiation is strategic: it does not own retail pharmacies, avoiding conflicts of interest and reinforcing trust—evidenced by an NPS of 71 (3Q 2025)—which helps it win share from vertically integrated rivals. Beyond wholesale, Humaneva has built a major independent European clinical research network (including Germany and the US) with backlog above USD 357m, while Świat Zdrowia expands medical care reach through owned and partner facilities. The investment debate centers on whether these higher-margin segments can scale to re-rate margins without undermining the stability of the regulated wholesale base.